Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Warts 1Stage I Prostate Adenocarcinoma AJCC v7 1Prostate Adenocarcinoma 1

Interventions

Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3relugolix 2luprolide acetate gel depot 2enzalutamide 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiosurgery 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1gallium 68 PSMA-11 1darolutamide 1abiraterone 1X-Rays 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radium-223 1Radiotherapy, Image-Guided 1Radiation Dose Hypofractionation 1Proton Therapy 1Prednisone 1Lymph Node Excision 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Salicylic Acid × 1 year × Clear all
NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡